Compounds with optimized pharmacological properties are available for preclinical research to explore novel disease biology and advance scientific knowledge. These compounds have been selected based on potency at the target and suitability for use in cellular/tissue systems in vitro (human or animal) as well as animal models in vivo.
Let’s Partner for Preclinical Research
AstraZeneca (AZ) is inviting disease area experts and scientists to partner with each other, with public or private funding parties, and with AZ to brainstorm, design, and execute preclinical translational research to provide groundbreaking scientific data. The aim is to generate high quality, novel data to support the future discovery and development of new therapeutics through target validation, efficacy in models of disease, and mechanistic insight into the pathophysiology of human disease.
Types of Preclinical Studies Considered
- In vitro studies which support understanding of disease biology using cells and/or ex vivo tissues from humans or animals.
- In vivo animal studies in models which have translatable endpoints to human disease which could be used to support progression to clinical studies.
- Combination of compounds/mechanisms studies to uncover synergies between pathways leading to novel insight into disease and potential therapies.
Next Steps for Interested Investigators
- Choose a compound: Take a look at the list of compounds and targets to see if there is a compound(s)/mechanism(s) of interest to you.
- To request a compound: A research proposal (2 – 3 pages) is required when requesting a compound. Please carefully review the guidance on submitting a preclinical research proposal and details of the review process.
- Submitting your proposal: Submit your preclinical research proposal.